Another Roche TIGIT disappointment
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
The company is stepping back in second-line breast cancer.
First-in-human study listings include EOS-215 and RO7673396.
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.